As the sector stands at a crossroads, the traditional pharmaceutical business model may become obsolete. Although it may be too late to halt its decline, it’s certainly not too late to rethink how pharmaceuticals can adapt and thrive in the face of shifting payer attitudes and patient empowerment.
Anyone taking a cursory glance at the current pharmaceutical industry would think that all is well. However, two seismic shifts are set to disturb the industry status quo: pressure to drive drug prices down and a shift from treatment to prediction, prevention and complete cures.
Taking a closer look at these shifts, KPMG’s recent white paper Pharma Outlook 2030: From evolution to revolution skips ahead to a 2030 scenario to examine the trends revolutionizing the sector – trends that are expected to have a dramatic impact.